These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The management of fistulizing oral Crohn's disease with infliximab. Staines KS; Green R; Felix DH J Oral Pathol Med; 2007 Aug; 36(7):444-6. PubMed ID: 17617840 [TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924 [TBL] [Abstract][Full Text] [Related]
6. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?]. Bode M; Eder S; Schürmann G Z Gastroenterol; 2008 Dec; 46(12):1376-83. PubMed ID: 19053007 [TBL] [Abstract][Full Text] [Related]
7. How deep is remission in perianal Crohn's disease and do imaging modalities matter? Savoye G; Savoye-Collet C Am J Gastroenterol; 2010 Jun; 105(6):1445-6; author reply 1446. PubMed ID: 20523317 [No Abstract] [Full Text] [Related]
8. [When should anti-TNF-alpha treatment in Crohn disease be terminated?]. Moum B Tidsskr Nor Laegeforen; 2010 Mar; 130(5):474. PubMed ID: 20224609 [No Abstract] [Full Text] [Related]
9. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease. de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M Digestion; 2008; 78(4):195-200. PubMed ID: 19122456 [TBL] [Abstract][Full Text] [Related]
10. Infliximab in fistulizing Crohn's disease. Osterman MT; Lichtenstein GR Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814 [TBL] [Abstract][Full Text] [Related]
11. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease. Desai AA; Marks DJ Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275 [No Abstract] [Full Text] [Related]
12. Treatment of Crohn's disease at the turn of the century. Bickston SJ; Cominelli F N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110 [No Abstract] [Full Text] [Related]
13. [Common variable immunodeficiency and sarcoidosis: what is the link?]. Agostini C; Semenzato G Ann Ital Med Int; 2002; 17(2):77-80. PubMed ID: 12150049 [No Abstract] [Full Text] [Related]
14. Medical therapy for refractory pediatric Crohn's disease. Faubion WA; Bousvaros A Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1199-213. PubMed ID: 16872913 [TBL] [Abstract][Full Text] [Related]
15. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease. Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656 [No Abstract] [Full Text] [Related]
16. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?]. Moum B Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118 [No Abstract] [Full Text] [Related]
17. Biologic therapy in Crohn's disease. Williams MD; Omran ML; Gordon GL Mo Med; 2009; 106(5):356-60. PubMed ID: 19902717 [TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. Fernández-Nebro A; Ureña I; Irigoyen MV; García-Vicuña R Gut; 2006 Nov; 55(11):1666-7; author reply 1667. PubMed ID: 17047117 [No Abstract] [Full Text] [Related]